In the SURMOUNT-1 trial, tirzepatide 15 mg produced roughly 21% average body-weight reduction over 72 weeks (Jastreboff et al., NEJM 2022), compared with roughly 15% for single-pathway GLP-1 compounded Semaglutide (STEP 1)
In everyday terms, it can feel like a running commentary: what is in the cupboard, when you can eat next, whether you should have something sweet, whether you have already eaten too much, or whether you should compensate later
I was curious whether tirzepatide or retatrutide is the better GLP-1, so I evaluated them properly through: 3 variables: weight loss, muscle loss, side effects
Cicho-LachHMichalakA
Moreover, in individuals with type 2 diabetes, metformin may provide cardiovascular protection that is not solely attributed to its glucose-lowering effects, as it also has antihypertensive effects [23]
PMID: 20877974